KCNH2 and breast carcinoma: The antitumor potential of the hERG activator NS1643 in breast cancer cells has been well- documented in a series of investigations (Breuer, et al., 2019; Fukushiro-Lopes, et al., 2018; Jiang, et al., 2022; Lansu and Gentile, 2013; Perez-Neut, et al., 2016).